The study by Wium-Andersen et al. (2019) demonstrated that patients with diabetes who used metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, or sodium-glucose cotransporter 2 (SGLT2) inhibitors had lower odds for developing dementia. Here, SLC5A2 is linked to dementia.